Indivior Pharmaceuticals, Inc. - 8-K Filing
Indivior declares $8.13/share special cash dividend contingent on merger with Supernus closing November 2, 2026 (Items: 7.01 Regulation FD Disclosure, 8.01 of this Current Report on Form 8-K), 9.01 Financial Statements and Exhibits)
Tickers: $INDV